| 摘要 |
<p>The invention relates to the use of those 5-HT3 receptor antagonists, which are active in the Rat Model of Colo-rectal Distension at a dose determined as the dose at which 5-HT3 receptor antagonist activity is observed in standard tests, such as the Bezold-Jarisch model, in the treatment of visceral pain, such as the pain symptoms of IBS, and also migraine.</p> |
